Pyrrole sulfonyl derivative as well as preparation method and application thereof
By designing new pyrrole sulfonyl derivatives, the limitations of existing proton pump inhibitors and potassium competitive acid blockers in pharmacokinetics and pharmacodynamics have been solved, and excellent gastric acid secretion inhibition and safety have been achieved. , improving therapeutic effect and pharmacokinetic properties.
Patent Information
- Application Number
- CN202410509076.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-28
- Filing Date
- 2024-04-26
- Publication Date
- 2024-11-05
AI Technical Summary
Existing proton pump inhibitors and potassium competitive acid blockers have limitations in pharmacokinetics and pharmacodynamics, affecting therapeutic effects, and lack new compounds with rich structural types to improve efficacy and safety.
A new pyrrole sulfonyl derivative and its pharmaceutically acceptable salts, tautomers or stereoisomers are designed for use as gastric acid secretion inhibitors and potassium ion competitive acid blockers, with Excellent safety and metabolic stability.
The pyrrole sulfonyl derivative exhibits excellent gastric acid secretion inhibitory activity, has good pharmacokinetic properties, significant half-life prolongation, improves the nocturnal acid breakthrough phenomenon, and shows low toxic side effects and high safety performance.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to a new type of pyrrole sulfonyl derivatives, a preparation method thereof, a pharmaceutical composition containing the derivatives, and the use of the derivatives as therapeutic agents, especially as gastric acid secretion inhibitors and potassium ion competitive acid blockers (P-CABs). Background Art
[0002] There are 120 million patients with gastrointestinal diseases in China, including Helicobacter pylori infection, gastroesophageal reflux, peptic ulcer, duodenal ulcer, gastric ulcer and esophagitis. The incidence of peptic ulcer is 10%, and the incidence of chronic gastritis is 30%. Long-term gastrointestinal diseases can gradually develop into gastrointestinal cancer. Among the six most common cancers in the world, five are related to the digestive tract, including gastric cancer, liver cancer, esophageal cancer, intestinal cancer, and pancreatic cancer. With the development of society and the change of people's lifestyles, the incidence of stomach-related diseases caused by smoking, drinking, emotional stress, staying up late, drug stimulation, and the Chinese people's preference for sour and spicy eating habits is gradually increasing. Peptic ulcer is seriously affecting people's work and life. At present, the medical community is still unclear about its exact pathogenesis, but inhibiting gastric acid secretion has become the recognized first choice for treating such diseases.
[0003] In 1987, the first proton pump inhibitor (PPI) omeprazole was successfully developed by AstraZenaca and first launched in Sweden. It is the world's first proton pump inhibitor used in clinical practice and has the strongest effect in inhibiting gastric acid. It is used to treat duodenal ulcers, Zollinger-Ellison syndrome, gastric ulcers and reflux esophagitis. Subsequently, several PPIs products were launched around the world. After years of clinical application, PPIs have become the first choice for the treatment of gastric acid-related diseases. Proton Pump is also called gastric acid pump. Its essence is H + / K + -ATPase (H + / K + -ATPase), which is the gastric secretion of H + The final common pathway is present on the cell membrane of the secretory tubules of gastric parietal cells and uses ATP degradation to provide energy for H + , K + exchange, specifically H +Pumped into the gastric cavity, it forms a strong acid state in the stomach. The first generation of PPIs has a significant inhibitory effect on basal, nocturnal gastric acid, gastric acid secretion stimulated by pentagastrin, test meals, etc. However, due to limitations in pharmacokinetics and pharmacodynamics, including bioavailability, the effect of administration time on drug efficacy, slow nocturnal acid breakthrough (NAB), instability under acidic conditions (often need to be prepared into enteral preparations, which take several hours to show effects), and dependence on CYP450 enzymes (the inhibitory effect of gastric acid secretion varies significantly from person to person), the therapeutic effect and clinical application are affected. Compared with the first generation of PPIs, the new generation of PPIs has obvious advantages in the treatment of gastroesophageal reflux disease (GERD) and other acid-related diseases.
[0004] Potassium-Competitive Acid Blockers (P-CABs) are a new type of acid inhibitors that competitively and reversibly bind to H + Inhibit H + / K + -ATPase activity, and its mechanism of action is significantly different from that of traditional PPIs, so it can be called an acid pump blocker. P-CABs are lipophilic, weakly alkaline, have a high dissociation constant, a long half-life, are stable in acidic conditions, are not primarily metabolized by CYP2C19, and have good tolerance and dependence. In an acidic environment, P-CABs immediately ionize, and the ionized form inhibits H + / K + -ATPase, inhibits H + Transport and acid secretion into the gastric cavity, without the need for microcapsules and microtubules concentrated in the gastric parietal cells and acid activation, can quickly increase the pH value in the stomach, and the enzyme activity is restored after dissociation. After oral administration, humans and animals can absorb it rapidly and reach the peak plasma concentration. Clinical and animal experiments have also shown that P-CABs are faster than PPIs or histamine receptor 2 (Histamine receptor 2, H2) blockers, have a stronger effect on increasing pH, and the blood drug concentration is linearly related to the oral dosage, indicating that this type of drug can achieve the optimal acid suppression state relatively easily and has obvious advantages. Takeda's Vonoprazan Fumarate was approved in Japan in December 2014; it was approved for import in China in December 2019, and some P-CABs preparations have entered clinical research.
[0005] Currently, a series of patent applications for P-CABs are disclosed, including WO2005041961A1, WO2006134460A1, WO2009041447A1 or WO2010021149A1, etc.
[0006] Although a series of P-CABs drugs or compounds have been disclosed, there is still a need to develop new compounds with richer structural types, better efficacy and greater safety. After continuous efforts, the present invention designs compounds having a structure represented by general formula (I) or general formula (III), and finds that compounds having such structures exhibit excellent effects, have little toxic side effects, and have good safety and metabolic stability. Summary of the invention
[0007] In order to solve the above problems in the prior art, the object of the present invention is to provide a new pyrrole sulfonyl derivative, a pharmaceutically acceptable salt thereof, a tautomer or a stereoisomer thereof, so as to screen out compounds having excellent performance in terms of effectiveness, safety and selectivity for use as gastric acid secretion inhibitors and potassium ion competitive acid blockers (P-CABs).
[0008] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0009] A pyrrole sulfonyl derivative, its tautomer or stereoisomer, and a pharmaceutically acceptable salt thereof, wherein the structure of the pyrrole sulfonyl derivative is shown in formula (I):
[0010]
[0011] Wherein, T is selected from O or C 1-6 alkyl;
[0012] When T is selected from O, X is selected from not present, R2 is selected from C 2-6 alkenyl;
[0013] When T is selected from C 1-6 When alkyl, X is selected from O, S, NH, S(O) m , R2 is selected from H, C 1-6 Alkyl, -C(=O)-C 1-6 Alkyl, C 2-6 Alkenyl, the C 1-6 The alkyl group may be optionally further substituted with methoxy, halogen;
[0014] R1 is selected from halogen;
[0015] R3 is selected from H, halogen, CH3O-;
[0016] Z1 and Z2 are each independently selected from C and N;
[0017] m is selected from 1 and 2;
[0018] n is selected from 0, 1, 2, 3, 4, 5.
[0019] In some preferred embodiments provided by the present invention, the structure of the pyrrole sulfonyl derivative is shown in formula (II):
[0020]
[0021] Wherein, X is selected from O, S, NH, S(O) m ;
[0022] R1, R2, n, m, Z1 and Z2 are as defined above.
[0023] Preferably, R1 is selected from fluorine; n is selected from 0, 1, and 2.
[0024] In another embodiment provided by the present invention, the structure of the pyrrole sulfonyl derivative is shown in formula (III):
[0025]
[0026] Among them, R a Selected from H, halogen, C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 Alkyl; among which C 1-6 The alkyl group may be optionally further substituted by 1, 2 or 3 fluorine atoms; the halogen is preferably a fluorine atom; R1, R3, n, Z1 and Z2 are as defined above.
[0027] Preferably, the pyrrole sulfonyl derivative is selected from any one of the following structures:
[0028]
[0029]
[0030]
[0031] Preferably, the pyrrole sulfonyl derivative is selected from any one of the following structures:
[0032]
[0033] On the other hand, the present invention provides a pharmaceutical composition, which comprises a pyrrole sulfonyl derivative, a pharmaceutically acceptable salt thereof, a tautomer or a stereoisomer thereof, and a pharmaceutically acceptable carrier and / or excipient.
[0034] In another aspect, the present invention provides a pyrrole sulfonyl derivative, a pharmaceutically acceptable salt thereof, a tautomer thereof or a stereoisomer thereof or a pharmaceutical composition as described above for use in the preparation of a gastric acid secretion inhibitor, H + / K + - Use in ATPase inhibitors or potassium ion competitive acid blockers.
[0035] The present invention provides a use of the above-mentioned pyrrole sulfonyl derivative, its pharmaceutically acceptable salt, its tautomer or its stereoisomer or the above-mentioned pharmaceutical composition in preparing drugs for treating or preventing the following diseases: peptic ulcer, Zollinger-Ellison syndrome, gastric erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease, Barrett's esophagitis, functional dyspepsia, Helicobacter pylori infection, gastric cancer, gastric MALT lymphoma, ulcer caused by nonsteroidal anti-inflammatory drugs, hyperacidity caused by postoperative stress or ulcer caused by postoperative stress; or use in preparing drugs for inhibiting upper gastrointestinal bleeding caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis or invasive stress. At the same time, the pyrrole sulfonyl derivative provided by the present invention has less toxic and side effects, better safety and metabolic stability than the prior art.
[0036] The present invention provides a pyrrole sulfonyl derivative with a new structure. The test results show that the pyrrole sulfonyl derivative exhibits excellent gastric acid secretion inhibition and potassium ion competitive acid blocker (P-CABs) activity, and can be used to prepare drugs for treating or preventing peptic ulcer, Zollinger-Ellison syndrome, gastric erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease, Barrett's esophagitis, functional dyspepsia, Helicobacter pylori infection, gastric cancer, gastric MALT lymphoma, ulcers caused by non-steroidal anti-inflammatory drugs, hyperacidity caused by postoperative stress or ulcers caused by postoperative stress; or in the preparation of drugs for inhibiting upper gastrointestinal bleeding caused by septic ulcers, acute stress ulcers, hemorrhagic gastritis or invasive stress. And the pyrrole sulfonyl derivative provided by the present invention has small toxic and side effects and excellent safety performance; it shows good pharmacokinetic properties, significant half-life extension, and more sustained acid suppression effect, and is expected to improve the nocturnal acid breakthrough phenomenon of proton pump inhibitor drugs in the prior art.
[0037] The present invention provides a pyrrole sulfonyl derivative as shown in formula (I):
[0038]
[0039] The structural formula disclosed therein is different from the structural formula disclosed in the patent CN115594623A previously applied by the applicant, as shown in control group 1 and control group 2. Compared with the structural formula disclosed in the patent CN115594623A previously applied by the applicant, the compound provided by the present invention has achieved unexpected technical effects.
[0040] BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 : Manual patch clamp hERG current test instruction voltage program diagram. DETAILED DESCRIPTION
[0042] The present invention is further described below by way of examples, but the examples are not intended to limit the scope of protection of the present invention.
[0043] Pd2(dba)3: trisdibenzylideneacetonedipalladium;
[0044] Pd(dppf)Cl2: 1,1'-bis(diphenylphosphinoferrocene)palladium dichloride;
[0045] Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene;
[0046] DIEA: N,N-diisopropylethylamine;
[0047] DMEDA: N,N'-dimethylethylenediamine;
[0048] Trt-Cl: triphenylmethane;
[0049] DCDMH: dichlorohydantoin;
[0050] DMAP: 4-dimethylaminopyridine;
[0051] Example 1
[0052] Synthesis of {[5-(2-fluorophenyl)-1-{3-[(2-methoxyethoxy)methyl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (Compound 249)
[0053]
[0054] Step 1: Synthesis of 1-bromo-3-[(2-methoxyethoxy)methyl]benzene (249-3)
[0055] Compound 249-1 (2.0 g, 10.7 mmol) was dissolved in N, N-dimethylformamide (30 mL), and then compound 249-2 (3.0 g, 21.4 mmol), potassium iodide (0.9 g, 5.4 mmol) and cesium carbonate (7.0 g, 21.4 mmol) were added. The mixture was stirred at 80°C overnight in a sealed tube. Ethyl acetate (100 mL) was added to the reaction system, and the mixture was washed with saturated brine (25 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V正己烷 :V 乙酸乙酯 =20:1) to obtain compound 249-3 (1.0 g, colorless oil, yield: 38.2%).
[0056] Step 2: Synthesis of 1-(benzylthio)-3-[(2-methoxyethoxy)methyl]benzene (249-4)
[0057] Compound 249-3 (1.0 g, 4.08 mmol) was dissolved in toluene (20 mL), and then Pd2(dba)3 (366 mg, 0.40 mmol), Xantphos (469 mg, 0.81 mmol), DIEA (1.6 g, 12.40 mmol) and benzyl mercaptan (529 mg, 4.26 mmol) were added in sequence, and stirred overnight at 100°C under nitrogen protection. After the reaction was completed, the mixture was cooled to room temperature, and water (30 mL) was added to the reaction system to quench the reaction, and the mixture was extracted with dichloromethane (40 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =20:1) to obtain compound 249-4 (580 mg, light yellow oil, yield: 49.3%).
[0058] Step 3: Synthesis of 3-[(2-methoxyethoxy)methyl]benzene-1-sulfonyl chloride (249-5)
[0059] Compound 249-4 (530 mg, 1.84 mmol) was dissolved in acetonitrile (8 mL), cooled to 0°C, and then glacial acetic acid (0.8 mL), water (0.4 mL) and DCDMH (435 mg, 2.21 mmol) were added in sequence, and the mixture was kept warm for 10 minutes. After the reaction was completed, ethyl acetate (30 mL) was added to the reaction system, and the mixture was washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 二氯甲烷 =5:1) to obtain compound 249-5 (330 mg, yellow oil, yield: 67.8%).
[0060] Step 4: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-{3-[(2-methoxyethoxy)methyl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (249-7)
[0061] Compound 249-6 (250 mg, 0.82 mmol) was dissolved in N, N-dimethylformamide (5 mL), cooled to 0°C, sodium hydride (49 mg, 1.23 mmol, 60% w / w) was added, and stirred at room temperature for half an hour. Compound 249-5 (283 mg, 1.07 mmol) was then added and stirred at room temperature for 2 hours. The reaction was quenched with saturated ammonium chloride (25 mL), extracted with ethyl acetate (15 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 249-7 (400 mg, brown oil, yield: 91.4%), [M+H] + :533.20.
[0062] Step 5: Synthesis of {[5-(2-fluorophenyl)-1-{3-[(2-methoxyethoxy)methyl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (249)
[0063] Compound 249-7 (400 mg, 0.75 mmol) was dissolved in ethyl acetate (3 mL), and a hydrochloric acid ethyl acetate solution (2 M, 15 mL) was added and stirred for 2 hours. The reaction solution was concentrated and slurried with ether (10 mL) to give compound 249 (300 mg, white solid, yield: 85.2%), [M+H] + :433.16.
[0064] 1 H NMR (400MHz, CD3OD) δ7.78 (s, 1H), 7.66 (d, J=7.2Hz, 1H), 7.55-7.38 (m, 4H), 7.20 (t, J=7.6Hz, 1H), 7. 12-7.08 (m, 2H), 6.40 (s, 1H), 4.53 (s, 2H), 4.11 (s, 2H), 3.63-3.59 (m, 4H), 3.40 (s, 3H), 2.72 (s, 3H).
[0065] Example 2
[0066] Synthesis of {[5-(2-fluorophenyl)-1-(3-{[(2-methoxyethyl)amino]methyl}benzenesulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine dihydrochloride (Compound 252)
[0067]
[0068] Step 1: Synthesis of [(3-bromophenyl)methyl](2-methoxyethyl)amine (252-2)
[0069] Compound 252-1 (600 mg, 3.22 mmol) was dissolved in N, N-dimethylformamide (6 mL), and then compound 249-2 (671 mg, 4.83 mmol) and potassium carbonate (890 mg, 6.44 mmol) were added and stirred at room temperature overnight. Water (30 mL) was then added to the reaction system to quench the reaction, and the mixture was extracted with ethyl acetate (60 mL). The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =20:1) to obtain compound 252-2 (760 mg, yellow oil, yield: 96.5%).
[0070] Step 2: Synthesis of tert-butyl N-[(3-bromophenyl)methyl]-N-(2-methoxyethyl)carbamate (252-3)
[0071] Compound 252-2 (760 mg, 3.11 mmol) and di-tert-butyl dicarbonate (814 mg, 3.73 mmol) were dissolved in dichloromethane (8 mL), and triethylamine (629 mg, 6.22 mmol) was added and reacted at room temperature for 3 hours. After the reaction was completed, the mixture was directly dried and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =6:1) to obtain compound 252-3 (890 mg, transparent oil, yield: 83.0%).
[0072] Step 3: Synthesis of tert-butyl N-{[3-(benzylthio)phenyl]methyl}-N-(2-methoxyethyl)carbamate (252-4)
[0073] Compound 252-3 (810 mg, 2.35 mmol) was dissolved in toluene (15 mL), and then Pd2(dba)3 (110 mg, 0.12 mmol), Xantphos (69 mg, 0.12 mmol), DIEA (607 mg, 4.70 mmol) and benzyl mercaptan (322 mg, 2.59 mmol) were added in sequence, and stirred overnight at 105°C under nitrogen protection. After the reaction was completed, the mixture was cooled to room temperature, and water (30 mL) was added to the reaction system to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL). The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =8:1) to obtain compound 252-4 (720 mg, brown oil, yield: 79.0%).
[0074] Step 4: Synthesis of tert-butyl N-{[3-(chlorosulfonyl)phenyl]methyl}-N-(2-methoxyethyl)carbamate (252-5)
[0075] Compound 252-4 (720 mg, 1.86 mmol) was dissolved in acetonitrile (20 mL), cooled to 0°C, and then glacial acetic acid (1 mL), water (1 mL) and DCDMH (733 mg, 3.72 mmol) were added in sequence, and the mixture was kept warm for 2 hours. After the reaction was completed, ethyl acetate (60 mL) was added to the reaction system, and the mixture was washed with saturated brine (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =6:1) to obtain compound 252-5 (665 mg, light yellow oil, yield: 98.4%).
[0076] Step 5: Synthesis of tert-butyl N-({1-[3-({[(tert-butoxy)carbonyl](2-methoxyethyl)amino}methyl)benzenesulfonyl]-5-(2-fluorophenyl)-1H-pyrrol-3-yl}methyl)-N-methylcarbamate (252-6)
[0077] Compound 249-6 (200 mg, 0.66 mmol) was dissolved in N, N-dimethylformamide (4 mL), cooled to 0°C, sodium hydride (42 mg, 1.06 mmol, 60% w / w) was added, and stirred at room temperature for half an hour. Compound 252-5 (313 mg, 0.86 mmol) was then added, and stirred at room temperature overnight. The reaction was quenched with saturated ammonium chloride (20 mL), extracted with ethyl acetate (15 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and first purified by column chromatography (V 正己烷 :V 乙酸乙酯 =4:1) and then purified by reverse phase preparation to obtain compound 252-6 (57 mg, transparent oil, yield: 13.7%), [M+Na] + :654.27.
[0078] Step 6: Synthesis of {[5-(2-fluorophenyl)-1-(3-{[(2-methoxyethyl)amino]methyl}benzenesulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine dihydrochloride (252)
[0079] Compound 252-6 (57 mg, 0.09 mmol) was dissolved in dichloromethane (1.5 mL), and a hydrochloric acid ethyl acetate solution (2 M, 3 mL) was added and stirred for 2 hours. The reaction solution was filtered, and the filter cake was washed with dichloromethane (2 mL × 3) and then dried to obtain compound 252 (38 mg, white solid, yield 83.5%), [M+H]+ :432.19.
[0080] 1 HNMR (400MHz, CD3OD) δ7.85-7.77 (m, 3H), 7.59 (t, J=7.8Hz, 1H), 7.53-7.47 (m, 2H), 7.21-7.16 (m, 1H), 7.13-7.07 (m, 2H) , 6.41 (d, J=1.8Hz, 1H), 4.25 (s, 2H), 4.11 (s, 2H), 3.66 (t, J=5.0Hz, 2H), 3.40 (s, 3H), 3.22 (t, J=5.0Hz, 2H), 2.72 (s, 3H).
[0081] Example 3
[0082] Synthesis of {[5-(2-fluorophenyl)-1-[3-(prop-2-en-1-oxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (Compound 253)
[0083]
[0084] Step 1: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-[3-(prop-2-en-1-oxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (253-3)
[0085] Compound 253-1 (200 mg, 0.43 mmol) was dissolved in N, N-dimethylformamide (5 mL), and then cesium carbonate (280 mg, 0.86 mmol) and compound 253-2 (51 mg, 0.66 mmol) were added, and the reaction was carried out at 50°C for 2 hours in a sealed tube. After the reaction was completed, the reaction system was cooled to room temperature, and water (25 mL) was added to the reaction system, and extracted with ethyl acetate (10 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Compound 253-3 (180 mg, brown oil, yield: 82.8%) was obtained by reverse phase preparation and purification, [M+H] + :501.20. Step 2: Synthesis of {[5-(2-fluorophenyl)-1-[3-(prop-2-en-1-oxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (253)
[0086] Compound 253-3 (180 mg, 0.36 mmol) was dissolved in ethyl acetate (1 mL), and a hydrochloric acid ethyl acetate solution (2 M, 5 mL) was added and stirred for 2 hours. The reaction solution was concentrated and slurried with ether (10 mL) to give compound 253 (145 mg, white solid, yield: 92.3%), [M+H]+ :401.14.
[0087] 1 H NMR (400MHz, CD3OD) δ7.78 (s, 1H), 7.54-7.38 (m, 1H), 7.40 (t, J=8.0Hz, 1H), 7.26-7.16 (m, 2H), 7.15-7.06 (m, 3H), 6.93-6.89 (m, 1 H), 6.42 (s, 1H), 6.08-5.98 (m, 1H), 5.40 (d, J=16Hz, 1H), 5.30 (d, J=10.4Hz, 1H), 4.51 (d, J=5.2Hz, 2H), 4.11 (s, 2H), 2.72 (s, 3H).
[0088] Example 4
[0089] Synthesis of {[5-(2-fluorophenyl)-1-{[5-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (Compound 257)
[0090]
[0091] Step 1: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-{[5-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (257-3)
[0092] Compound 257-1 (1.0 g, 1.91 mmol), compound 257-2 (236 mg, 2.87 mmol), cuprous iodide (72 mg, 0.38 mmol), DMEDA (67 mg, 0.76 mmol) and potassium carbonate (792 mg, 5.73 mmol) were dissolved in dioxane (10 mL), heated to 120 ° C under nitrogen protection and stirred overnight, cooled to room temperature, ethyl acetate (50 mL) was added to dilute the reaction system, washed with saturated ammonium chloride aqueous solution (20 mL) and saturated brine (20 mL) in turn, dried over anhydrous sodium sulfate, filtered, the solvent was concentrated and then column chromatography (V 正己烷 :V 乙酸乙酯 =4:1) to obtain compound 257-3 (580 mg, yellow oil, yield: 57.9%), [M+H] + :526.19.
[0093] Step 3: Synthesis of {[5-(2-fluorophenyl)-1-{[5-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (257)
[0094] Compound 257-3 (580 mg, 1.10 mmol) was dissolved in ethyl acetate (5 mL), and a hydrochloric acid ethyl acetate solution (2 M, 5 mL) was added at room temperature. After stirring overnight, the solid was filtered and dried to obtain compound 257 (273 mg, white solid, yield 53.6%), [M+H] + :426.14.
[0095] 1 H NMR (400MHz, CD3OD) δ9.22 (d, J=2.4Hz, 1H), 8.42 (d, J=2.0Hz, 1H), 8.18-8.09 (m, 2H), 7.86 (d, J=2.0Hz, 1H), 7.65 (s, 1H) , 7.48-7.45 (m, 1H), 7.22-7.13 (m, 2H), 7.10-7.00 (m, 1H), 6.46 (d, J=2.0Hz, 1H), 4.11 (s, 2H), 2.72 (s, 3H), 2.18 (s, 3H).
[0096] Example 5
[0097] Synthesis of {[5-(2-fluorophenyl)-1-({5-[4-(methoxymethyl)-1H-pyrazol-1-yl]pyridin-3-yl}sulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine (Compound 264)
[0098]
[0099] Step 1: Synthesis of methyl 1-(triphenylmethyl)-1H-pyrazole-4-carboxylate (264-2)
[0100] Sodium hydride (4.5 g, 113.0 mmol, 60% w / w) was dissolved in N, N-dimethylformamide (200 mL), and compound 264-1 (9.5 g, 75.3 mmol) was added in batches at 0°C, and stirred at 0°C for 1.5 hours. Trt-Cl (21.0 g, 75.3 mmol) was added at 0°C, and stirred for another 1.5 hours. After the reaction was complete, water (200 mL) was added at 0°C to quench the reaction, and ethyl acetate (300 mL×2) was used for extraction. The organic phases were combined, washed with water (200 mL×2) and saturated brine (200 mL×2) in sequence, dried over anhydrous sodium sulfate, and concentrated to obtain compound 264-2 (27.5 g, crude product).
[0101] Step 2: Synthesis of [1-(triphenylmethyl)-1H-pyrazol-4-yl]methanol (264-3)
[0102] Compound 264-2 (27.5 g, crude product) was dissolved in tetrahydrofuran (700 mL), and lithium aluminum tetrahydride (3.4 g, 89.5 mmol) was added in batches at 0°C, and stirred at 0°C for 1.5 hours. After the reaction was complete, water (4 mL) was added dropwise at 0°C, and stirred at room temperature for half an hour, and then anhydrous sodium sulfate was added and stirred for half an hour. The crude product was filtered and concentrated to obtain a pulp (V 正己烷 :V 乙酸乙酯 =15:1), filtered and concentrated to obtain compound 264-3 (18.4 g, white solid, two-step yield: 71.7%).
[0103] Step 3: Synthesis of 4-(methoxymethyl)-1-(triphenylmethyl)-1H-pyrazole (264-4)
[0104] Sodium hydride (3.3 g, 82.0 mmol, 60% w / w) was dissolved in N, N-dimethylformamide (300 mL), and compound 264-3 (18.4 g, 54.0 mmol) was added at 0°C, stirred at 0°C for 1 hour, iodomethane (19.2 g, 135.0 mmol) was added, and stirred at room temperature for 3 hours. After the reaction was completed, saturated brine (200 mL) was added at 0°C to quench the reaction, and extracted with ethyl acetate (300 mL×2), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give compound 264-4 (19.0 g, white solid, yield: 99.2%).
[0105] Step 4: Synthesis of 4-(methoxymethyl)-1H-pyrazole (264-5)
[0106] Compound 264-4 (19.0 g, 53.6 mmol) was dissolved in a mixed solvent of methanol and dichloromethane (300 mL each), trifluoroacetic acid (100 mL) was added, and the mixture was refluxed at 75°C overnight. After the reaction was complete, the mixture was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =5:1~V 乙酸乙酯 :V 甲醇 =20:1) to obtain the product, which was diluted with dichloromethane (100 mL), washed with sodium bicarbonate (30 mL×2) and saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated to obtain compound 264-5 (1.9 g, white solid, yield: 31.6%), [M+H] + :113.10.
[0107] Step 5: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-({5-[4-(methoxymethyl)-1H-pyrazol-1-yl]pyridin-3-yl}sulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (264-6)
[0108] Compound 257-1 (1.5 g, 2.86 mmol), compound 264-5 (481 mg, 4.29 g mmol), cuprous iodide (545 mg, 2.86 mmol), DMEDA (504 mg, 5.72 mmol) and potassium carbonate (1.2 g, 8.58 mmol) were added to dioxane (30 mL) and reacted at 120° C. overnight. After the reaction was complete, diatomaceous earth was used for filtration, and the filter cake was washed with ethyl acetate (20 mL). The concentrated column chromatography (V 正己烷 :V 乙酸乙酯 =4:1) to obtain 1.2 g of the product, which was then purified by reverse phase preparation to obtain compound 264-6 (910 mg, light yellow oil, yield: 57.3%), [M+Na] + :578.24.
[0109] Step 6: Synthesis of {[5-(2-fluorophenyl)-1-({5-[4-(methoxymethyl)-1H-pyrazol-1-yl]pyridin-3-yl}sulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine (264)
[0110] Compound 264-6 (910 mg, 1.64 mmol) was dissolved in dichloromethane (15 mL), trifluoroacetic acid (5 mL) was added, and the mixture was stirred at room temperature for half an hour. After the reaction was complete, part of the solvent was concentrated, saturated sodium bicarbonate was added dropwise to adjust the pH to 8, and the mixture was extracted with dichloromethane (20 mL × 2), washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. Acetonitrile (10 mL) was added, stirred at 0°C for 1 hour, and filtered to obtain compound 264 (330 mg, white solid, yield: 44.2%), [M+H] + :456.18.
[0111] 1H NMR (400MHz, DMSO-d6) δ9.42 (d, J=2.4Hz, 1H), 9.19 (br, 1H), 8.74 (s, 1H), 8.46 (d, J=2.0Hz, 1H), 8.21 (t, J=2.4Hz, 1H), 7.92 (d, J=1.8 Hz, 1H), 7.88 (s, 1H), 7.54-7.51 (m, 1H), 7.25-7.11 (m, 3H), 6.62 (d, J=1.6Hz, 1H), 4.39 (s, 2H), 4.00 (s, 2H), 3.30 (s, 3H), 2.56 (s, 3H).
[0112] Example 6
[0113] Synthesis of {[5-(2-fluorophenyl)-1-{3-[4-(methoxymethyl)-1H-pyrazol-1-yl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine fumarate (Compound 261)
[0114]
[0115] Step 1: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-{3-[4-(methoxymethyl)-1H-pyrazol-1-yl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (261-2)
[0116] Compound 261-1 (1.5 g, 2.87 mmol), compound 264-5 (482 mg, 4.30 mmol), cuprous iodide (547 mg, 2.87 mmol), DMEDA (253 mg, 2.87 mmol) and potassium carbonate (1.2 g, 8.61 mmol) were added to dioxane (40 ml), nitrogen was replaced, and the system was stirred at 110° C. overnight. After the reaction was complete, diatomaceous earth was used for filtration, concentration was performed, and column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 261-2 (1.29 g, light red oil, yield: 81.1%), [M+Na] + :577.25.
[0117] Step 3: {[5-(2-fluorophenyl)-1-{3-[4-(methoxymethyl)-1H-pyrazol-1-yl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)
[0118] Synthesis of Amine Fumarate (261)
[0119] Compound 261-2 (1.29 g, 2.328 mmol) was dissolved in dichloromethane (20 mL), trifluoroacetic acid (5.0 mL) was added, and the system was stirred at room temperature for 15 minutes. After the reaction was complete, part of the solvent was concentrated, pH was adjusted to 8 with NaHCO3, and then extracted with dichloromethane (50 ml x 2), the organic phases were combined, washed with saturated brine (40 mL), dried, and concentrated to obtain a crude product, which was purified by reverse preparation to obtain 710 mg of free base as a light yellow oil. The free base was then dissolved in acetonitrile (20 mL), fumaric acid (190 mg, 1.64 mmol) was added, stirred overnight, and filtered to obtain compound 261 (770 mg, yield: 58.0%), [M+H] + :455.21.
[0120] 1 H NMR (400MHz, DMSO-d6) δ 8.56 (s, 1H), 8.17 (d, J = 8.4Hz, 1H), 7.89 (t, J = 2.0Hz, 1H), 7.80 (s, 1H), 7.76 (d, J = 1.6Hz, 1H), 7.67 (t, J = 8.0Hz, 1H), 7. 51-7.44(m, 1H), 7.35-7.30(m, 1H), 7.22-7.08(m, 3H), 6.50(s, 2H), 6.4 6(d, J=1.6Hz, 1H), 4.38(s, 2H), 3.88(s, 2H), 3.29(s, 3H), 2.43(s, 3H).
[0121] Example 7
[0122] Synthesis of ({1-[3-(ethoxymethyl)benzenesulfonyl]-5-(2-fluorophenyl)-1H-pyrrol-3-yl}methyl)(methyl)amine hydrochloride (Compound 275)
[0123]
[0124] Step 1: Synthesis of 1-bromo-3-(ethoxymethyl)benzene (275-1)
[0125] Compound 249-1 (2.0 g, 10.7 mmol) was dissolved in N, N-dimethylformamide (30 mL), cooled to 0°C, then sodium hydride (856 mg, 21.4 mmol, 60% w / w) was added, stirred for half an hour, and then iodoethane (2.5 g, 16.0 mmol) was added and stirred at room temperature for 2 hours. After the reaction was completed, saturated ammonium chloride solution (120 mL) was added to the reaction system to quench, extracted with ethyl acetate (50 ml × 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V乙酸乙酯 =20:1) to obtain compound 275-1 (2.1 g, colorless oil, yield: 91.3%).
[0126] Step 2: Synthesis of 1-(benzylthio)-3-(ethoxymethyl)benzene (275-2)
[0127] Compound 275-1 (1.0 g, 4.65 mmol) was dissolved in toluene (20 mL), and then Pd2(dba)3 (421 mg, 0.46 mmol), Xantphos (538 mg, 0.93 mmol), DIEA (1.8 g, 13.95 mmol) and benzyl mercaptan (635 mg, 5.11 mmol) were added in sequence, and stirred overnight at 100°C under nitrogen protection. After the reaction was completed, the mixture was cooled to room temperature, and water (100 mL) was added to the reaction system, and the mixture was extracted with dichloromethane (30 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =20:1) to obtain compound 275-2 (800 mg, light yellow oil, yield: 66.6%).
[0128] Step 3: Synthesis of 3-(ethoxymethyl)benzenesulfonyl chloride (275-3)
[0129] Compound 275-2 (800 mg, 3.10 mmol) was dissolved in acetonitrile (10 mL), cooled to 0°C, and then glacial acetic acid (0.2 mL), water (0.1 mL) and DCDMH (733 mg, 3.72 mmol) were added in sequence, and the mixture was kept warm for 10 minutes. After the reaction was completed, ethyl acetate (40 mL) was added to the reaction system, and the mixture was washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 二氯甲烷 =5:1) to obtain compound 275-3 (0.4 g, yellow oil, yield: 55.0%).
[0130] Step 4: Synthesis of tert-butyl N-({1-[3-(ethoxymethyl)benzenesulfonyl]-5-(2-fluorophenyl)-1H-pyrrol-3-yl}methyl)-N-methylcarbamate (275-4)
[0131] Compound 249-6 (0.2 g, 0.66 mmol) was dissolved in N, N-dimethylformamide (5 mL), cooled to 0°C, sodium hydride (53 mg, 1.32 mmol, 60% w / w) was added, and stirred at room temperature for half an hour. Compound 275-3 (185 mg, 0.79 mmol) was then added and stirred at room temperature for 2 hours. The reaction was quenched with saturated ammonium chloride (30 mL), extracted with ethyl acetate (15 mL×3), the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 275-4 (270 mg, brown oil, yield: 81.8%), [M+H] + :503.20.
[0132] Step 5: Synthesis of ({1-[3-(ethoxymethyl)benzenesulfonyl]-5-(2-fluorophenyl)-1H-pyrrol-3-yl}methyl)(methyl)amine hydrochloride (275)
[0133] Compound 275-4 (270 mg, 0.54 mmol) was dissolved in ethyl acetate (5 mL), and a hydrochloric acid ethyl acetate solution (2 M, 10 mL) was added and stirred for 2 hours. The reaction solution was concentrated and slurried with ether (20 mL) to give compound 275 (123 mg, white solid, yield 52.2%), [M+H] + :403.16.
[0134] 1 H NMR (400MHz, CD3OD) δ7.77 (s, 1H), 7.64 (d, J=7.5Hz, 1H), 7.54-7.38 (m, 4H), 7.18 (t, 1H), 7.14-7.06 (m , 2H), 6.40 (s, 1H), 4.48 (s, 2H), 4.10 (s, 2H), 3.57 (q, J=7.0Hz, 2H), 2.71 (s, 3H), 1.25 (t, J=7.0Hz, 3H).
[0135] Example 8
[0136] Synthesis of (3-{[2-(2-fluorophenyl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}phenyl)methanol hydrochloride (Compound 276)
[0137]
[0138] Step 1: Synthesis of methyl (3-bromophenyl)acetate (276-1)
[0139] Compound 249-1 (3.0 g, 16.0 mmol) was dissolved in tetrahydrofuran (40 mL), and then DMAP (391 mg, 3.2 mmol), triethylamine (4.9 g, 48.5 mmol) and acetic anhydride (2.5 g, 24.5 mmol) were added in sequence, and stirred at room temperature overnight. After the reaction was completed, water (150 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (40 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =20:1) to obtain compound 276-1 (3.5 g, light yellow oil, yield: 95.3%). Step 2: Synthesis of methyl [3-(benzylthio)phenyl]acetate (276-2)
[0140] Compound 276-1 (3.0 g, 13.10 mmol) was dissolved in toluene (40 mL), and then Pd2(dba)3 (1.2 g, 1.31 mmol), Xantphos (1.5 g, 2.60 mmol), DIEA (5.0 g, 38.76 mmol) and benzyl mercaptan (1.8 g, 14.42 mmol) were added in sequence, and stirred overnight at 100°C under nitrogen protection. After the reaction was completed, the mixture was cooled to room temperature, and water (160 mL) was added to the reaction system, and the mixture was extracted with dichloromethane (70 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =20:1) to obtain compound 276-2 (3.0 g, light yellow oil, yield: 84.1%).
[0141] Step 3: Synthesis of methyl [3-(chlorosulfonyl)phenyl]acetate (276-3)
[0142] Compound 276-2 (3.0 g, 11.0 mmol) was dissolved in acetonitrile (40 mL), cooled to 0°C, and then glacial acetic acid (0.8 mL), water (0.4 mL) and DCDMH (2.6 g, 13.2 mmol) were added in sequence, and the mixture was kept warm for 10 minutes. After the reaction was completed, ethyl acetate (100 mL) was added to the reaction system, and the mixture was washed with saturated brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 二氯甲烷 =5:1) to obtain compound 276-3 (2.1 g, light yellow oil, yield: 76.7%).
[0143] Step 4: Synthesis of methyl (3-{[4-({[(tert-butoxy)carbonyl](methyl)amino}methyl)-2-(2-fluorophenyl)-1H-pyrrol-1-yl]sulfonyl}phenyl)acetate (276-4)
[0144] Compound 249-6 (1.5 g, 4.93 mmol) was dissolved in N, N-dimethylformamide (20 mL), cooled to 0°C, sodium hydride (394 mg, 9.86 mmol, 60% w / w) was added, stirred at room temperature for half an hour, and then compound 276-3 (1.8 g, 7.40 mmol) was added, and stirred at room temperature for 2 hours. The reaction was quenched with saturated ammonium chloride (70 mL), extracted with ethyl acetate (25 mL×3), the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 276-4 (1.0 g, brown oil, yield: 39.3%), [M+H] + :517.17.
[0145] Step 5: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-[3-(hydroxymethyl)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (276-5)
[0146] Compound 276-4 (1.0 g, 1.94 mmol) was dissolved in methanol (10 mL), lithium hydroxide (139 mg, 5.82 mmol) was dissolved in water (5 mL) and added to the reaction solution, and stirred for 3 hours. Water (50 mL) was added for dilution, and the mixture was extracted with dichloromethane (20 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by reverse phase preparation to obtain compound 276-5 (560 mg, light yellow solid, yield: 61.0%), [M+H] + :475.18.
[0147] Step 6: Synthesis of (3-{[2-(2-fluorophenyl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}phenyl)methanol hydrochloride (276)
[0148] Compound 276-5 (200 mg, 0.42 mmol) was dissolved in ethyl acetate (5 mL), and a hydrochloric acid ethyl acetate solution (2 M, 10 mL) was added and stirred for 2 hours. The reaction solution was concentrated and slurried with ether (10 mL) to give compound 276 (72 mg, white solid, yield 41.6%), [M+H] + :375.12.
[0149] 1H NMR (400MHz, CD3OD) δ7.78 (d, J=1.8Hz, 1H), 7.65 (d, J=7.4Hz, 1H), 7.54-7.42 (m, 3H), 7.38 (d, J=8.0Hz, 1H), 7. 18 (t, J=7.5, 1.0Hz, 1H), 7.14-7.06 (m, 2H), 6.39 (d, J=8.7, 1.9Hz, 1H), 4.59 (s, 2H), 4.11 (s, 2H), 2.72 (s, 3H).
[0150] Example 9
[0151] Synthesis of {[5-(2-fluoropyridin-3-yl)-1-[3-(prop-2-en-1-oxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (Compound 280)
[0152]
[0153] Step 1: Synthesis of [(5-bromo-1H-pyrrol-3-yl)methyl](methyl)amine (280-2)
[0154] At room temperature, compound 280-1 (5.0 g, 28.74 mmol) was dissolved in methylamine methanol solution (50 mL, 30% w / w), stirred at room temperature for 2 hours, cooled to 0°C, added with sodium borohydride (2.2 g, 57.48 mmol), and kept warm until the reaction of compound 280-1 was complete as monitored by TLC. The reaction solution was quenched with saturated ammonium chloride solution (250 mL), and dichloromethane (100 mL) was added for mixed extraction. The aqueous phase was extracted once with dichloromethane (100 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 280-2 (4.23 g, brown-yellow oil, yield: 77.9%).
[0155] Step 2: Synthesis of tert-butyl N-[(5-bromo-1H-pyrrol-3-yl)methyl]-N-methylcarbamate (280-3)
[0156] At room temperature, compound 280-2 (4.23 g, 22.37 mmol) was dissolved in dichloromethane (45 mL), triethylamine (4.53 g, 44.74 mmol) was added, and di-tert-butyl dicarbonate (5.37 g, 24.61 mmol) was slowly added dropwise. After the addition, the mixture was stirred at room temperature until the reaction of compound 280-2 was complete as monitored by TLC. The reaction solution was directly concentrated under reduced pressure, and the obtained crude product was purified by column chromatography (V 二氯甲烷 :V 甲醇 =30:1) to obtain compound 280-3 (5.91 g, yellow oil, yield: 91.3%).
[0157] Step 3: Synthesis of tert-butyl N-{[5-bromo-1-(3-methoxybenzenesulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (280-5)
[0158] At room temperature, compound 280-3 (2.0 g, 6.92 mmol) was dissolved in N, N-dimethylformamide (20 mL), cooled to 0°C, sodium hydride (0.55 g, 13.84 mmol, 60% w / w) was added, and compound 280-4 (2.00 g, 9.69 mmol) was slowly added dropwise after reacting for 30 minutes. After the addition, the reaction was stirred at room temperature until the reaction of compound 280-3 was complete as monitored by TLC. The reaction solution was quenched with water (80 mL), mixed and extracted with ethyl acetate (120 mL), the organic phase was washed with saturated sodium chloride solution (60 mL), dried over anhydrous sodium sulfate, filtered and concentrated, and the obtained crude product was purified by column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 280-5 (3.15 g, yellow oil, yield: 99.1%).
[0159] Step 4: Synthesis of tert-butyl N-{[5-(2-fluoropyridin-3-yl)-1-(3-methoxyphenylsulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (280-7)
[0160] At room temperature, compound 280-5 (1.0 g, 2.18 mmol) was dissolved in a mixed solvent of dioxane (10 mL) and water (2 mL), and compound 280-6 (369 mg, 2.62 mmol), Pd(dppf)Cl2 (161 mg, 0.22 mmol) and potassium phosphate (1157 mg, 5.45 mmol) were added in sequence, and the mixture was reacted at 80°C for 16 hours under nitrogen protection. The reaction solution was directly concentrated to dryness and column chromatography (V 正己烷 :V 乙酸乙酯 =1:1) to obtain compound 280-7 (610 mg, yellow oil, yield: 58.9%).
[0161] Step 5: Synthesis of 3-{[2-(2-fluoropyridin-3-yl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}phenol (280-8)
[0162] At room temperature, compound 280-7 (610 mg, 1.28 mmol) was dissolved in dichloromethane (5 mL), and a dichloromethane solution of boron tribromide (1 M, 5 mL) was added, and the reaction was stirred at room temperature until the reaction of compound 280-7 was complete as monitored by TLC. The reaction solution was adjusted to pH = 8 with sodium bicarbonate solution, and a mixed solvent of dichloromethane and methanol (V 二氯甲烷 :V甲醇 =10:1) for multiple extractions, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 280-8 (430 mg, yellow solid, yield 92.8%).
[0163] Step 6: Synthesis of tert-butyl 3-{[4-({[(tert-butoxy)carbonyl](methyl)amino}methyl)-2-(2-fluoropyridin-3-yl)-1H-pyrrol-1-yl]sulfonyl}phenyl carbonate (280-9)
[0164] At room temperature, compound 280-8 (430 mg, 1.19 mmol) was dissolved in dichloromethane (5 mL), triethylamine (361 mg, 3.57 mmol) was added, and di-tert-butyl dicarbonate (519 mg, 2.38 mmol) was slowly added dropwise. After the addition, the mixture was stirred at room temperature until the reaction of compound 280-8 was complete as monitored by TLC. The reaction solution was directly concentrated under reduced pressure, and the crude product was purified by column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 280-9 (360 mg, light yellow oil, yield 53.9%).
[0165] Step 7: Synthesis of tert-butyl N-{[5-(2-fluoropyridin-3-yl)-1-(3-hydroxybenzenesulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (280-10)
[0166] At room temperature, compound 280-9 (360 mg, 0.64 mmol) was dissolved in methanol (4 mL), potassium carbonate (88 mg, 0.64 mmol) was added, and the reaction was stirred at room temperature until the reaction of compound 280-9 was complete as monitored by TLC. The reaction solution was directly concentrated under reduced pressure, and the obtained crude product was purified by column chromatography (V 二氯甲烷 :V 甲醇 =30:1) to obtain compound 280-10 (200 mg, transparent oil, yield 67.6%).
[0167] Step 8: Synthesis of tert-butyl N-{[5-(2-fluoropyridin-3-yl)-1-[3-(prop-2-en-1-oxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (280-11)
[0168] Compound 280-10 (200 mg, 0.43 mmol), compound 253-2 (66 mg, 0.86 mmol) and cesium carbonate (280 mg, 0.86 mmol) were dissolved in N, N-dimethylformamide (5 mL), sealed and reacted at 50°C for 16 hours. Water (20 mL) and ethyl acetate (30 mL) were added to the reaction solution for mixed extraction, and the organic phase was washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the crude product was purified by column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 280-11 (170 mg, transparent oil, yield 78.2%), [M+H] + :502.17.
[0169] Step 9: Synthesis of {[5-(2-fluoropyridin-3-yl)-1-[3-(prop-2-en-1-oxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (280)
[0170] At room temperature, compound 280-11 (150 mg, 0.30 mmol) was dissolved in dichloromethane (2 mL), and a hydrochloric acid ethyl acetate solution (2 M, 4 mL) was added. The mixture was reacted at room temperature for 1 hour, and concentrated under reduced pressure. The concentrate was solidified by adding ether (4 mL), scraped and filtered, and dried to obtain compound 280 (120 mg, yellow-white solid, yield: 91.6%), [M+H] + :402.14.
[0171] 1 H NMR (400MHz, CD3OD) δ8.31 (d, J=4.8Hz, 1H), 7.81 (d, J=2.0Hz, 1H), 7.77-7.72 (m, 1H), 7.44 (t, J=8.0Hz, 1H), 7.41-7.37 (m, 1H), 7.27 (d, J=8.4Hz, 1H), 7.12-7.08 ( m, 1H), 6.96 (t, J=2.0Hz, 1H), 6.52 (d, J=2.0Hz, 1H), 6.08-6.00 (m, 1H), 5.40 (d, J =7.6Hz, 1H), 5.33-5.29 (m, 1H), 4.55 (d, J = 5.2Hz, 2H), 4.12 (s, 2H), 2.72 (s, 3H).
[0172] Example 10
[0173] Synthesis of ({[5-(2-fluorophenyl)-4-methoxy-1-[3-(prop-2-en-1-yloxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}(methyl)amine (Compound 281)
[0174]
[0175] Step 1: Synthesis of 1-(benzyloxy)-3-bromobenzene (281-2)
[0176] Compound 281-1 (2.0 g, 11.56 mmol) was dissolved in N, N-dimethylformamide (30 mL), and then cesium carbonate (7.5 g, 23.01 mmol) and benzyl bromide (2.9 g, 16.96 mmol) were added in sequence, and stirred at 50°C overnight. After the reaction was completed, water (160 mL) was added to the reaction system to quench the reaction, and the mixture was extracted with ethyl acetate (70 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =30:1) was purified to give compound 281-2 (2.8 g, white solid, yield: 92.1%).
[0177] Step 2: Synthesis of 1-(benzyloxy)-3-(benzylthio)benzene (281-3)
[0178] Compound 281-2 (1.0 g, 3.80 mmol) was dissolved in toluene (20 mL), and then Pd2(dba)3 (348 mg, 0.38 mmol), Xantphos (440 mg, 0.76 mmol), DIEA (1.5 g, 11.63 mmol) and benzyl mercaptan (518 mg, 4.17 mmol) were added in sequence, and stirred overnight at 100°C under nitrogen protection. After the reaction was completed, the mixture was cooled to room temperature, and water (100 mL) was added to the reaction system, and the mixture was extracted with dichloromethane (40 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =20:1) was purified to give compound 281-3 (1.1 g, colorless oil, yield: 94.5%).
[0179] Step 3: Synthesis of 3-(Benzyloxy)benzene-1-sulfonyl chloride (281-4)
[0180] Compound 281-3 (1.1 g, 3.59 mmol) was dissolved in acetonitrile (15 mL), cooled to 0°C, and then glacial acetic acid (0.3 mL), water (0.15 mL) and DCDMH (780 mg, 3.96 mmol) were added in sequence, and the mixture was kept warm for 10 minutes. After the reaction was completed, ethyl acetate (60 mL) was added to the reaction system, and the mixture was washed with saturated brine (25 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V二氯甲烷 =20:1) was purified to give compound 281-4 (800 mg, light yellow oil, yield: 78.8%).
[0181] Step 4: Synthesis of tert-butyl N-({1-[3-(benzyloxy)benzenesulfonyl]-5-(2-fluorophenyl)-4-methoxy-1H-pyrrol-3-yl}methyl)-N-methylcarbamate (281-6)
[0182] Compound 281-5 (340 mg, 1.02 mmol) was dissolved in N, N-dimethylformamide (5 mL), cooled to 0°C, sodium hydride (82 mg, 2.05 mmol, 60% w / w) was added, stirred at room temperature for half an hour, and then compound 281-4 (430 mg, 1.52 mmol) was added, and stirred at room temperature for 2 hours. The reaction was quenched with saturated ammonium chloride (25 mL), extracted with ethyl acetate (10 mL×3), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 281-6 (200 mg, yellow oil, yield: 33.9%), [M+H] + :581.20.
[0183] Step 5: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-(3-hydroxybenzenesulfonyl)-4-methoxy-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (281-7)
[0184] Compound 281-6 (200 mg, 0.34 mmol) was dissolved in methanol (5 mL), palladium carbon (60 mg, containing 5% palladium and 55% water) was added, and stirred overnight under a hydrogen system. The reaction solution was filtered and the filtrate was concentrated to obtain compound 281-7 (160 mg, colorless oil, yield: 94.7%), [M+H] + :491.16.
[0185] Step 6: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-4-methoxy-1-[3-(prop-2-en-1-yloxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (281-8)
[0186] Compound 281-7 (160 mg, 0.33 mmol) was dissolved in N, N-dimethylformamide (5 mL), and then cesium carbonate (212 mg, 0.65 mmol) and 3-chloropropylene (50 mg, 0.65 mmol) were added in sequence, and stirred at 50°C overnight. After the reaction was completed, water (25 mL) was added to the reaction system to quench the reaction, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =3:1) to obtain compound 281-8 (100 mg, yellow oil, yield: 57.8%), [M+H] + :531.18.
[0187] Step 7: Synthesis of ({[5-(2-fluorophenyl)-4-methoxy-1-[3-(prop-2-en-1-yloxy)benzenesulfonyl]-1H-pyrrol-3-yl]methyl}(methyl)amine (281)
[0188] Compound 281-8 (100 mg, 0.19 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the mixture was stirred for 2 hours. The reaction solution was poured into water (15 mL), and the pH was adjusted to 8 with sodium bicarbonate. The mixture was extracted with dichloromethane (8 mL×3). The organic phase was dried over anhydrous sodium sulfate and filtered. After the filtrate was concentrated, the crude product was purified by reverse phase preparation to obtain compound 281 (50 mg, light yellow oil, yield 61.6%), [M+H] + :431.2.
[0189] 1 H NMR (400MHz, CD3OD) δ7.68 (s, 1H), 7.56-7.49 (m, 1H), 7.40 (t, J=8.0Hz, 1H), 7.24 (d, J=8.0Hz, 1H), 7.19 (t, J=7.6Hz, 1H), 7.15-7.03 (m, 3H), 6. 88-6.85 (m, 1H), 6.13-5.98 (m, 1H), 5.40 (d, J=16Hz, 1H), 5.31 (d, J=10. 6Hz, 1H), 4.52 (d, J = 5.2Hz, 2H), 4.10 (s, 2H), 3.46 (s, 3H), 2.74 (s, 3H).
[0190] Embodiment 11
[0191] Synthesis of methyl (3-{[2-(2-fluorophenyl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}phenyl)acetate (Compound 284)
[0192]
[0193] Compound 276-4 (150 mg, 0.29 mmol) was dissolved in ethyl acetate (2 mL), and a hydrochloric acid ethyl acetate solution (2 M, 6 mL) was added, and the mixture was stirred for 2 hours. Water (10 mL) was added to the reaction solution, and the pH was adjusted to 8 with a saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (4 mL×3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel large plate chromatography (V 二氯甲烷 :V 甲醇 =15:1) to obtain compound 284 (60 mg, light yellow viscous substance, yield: 49.6%), [M+H] + :417.13.
[0194] 1 H NMR (400MHz, CD3OD) δ7.71 (d, J=1.6Hz, 1H), 7.67 (d, J=6.8Hz, 1H), 7.53-7.46 (m, 3H), 7.38 (s, 1H), 7.19 (t, J=7.6Hz, 1H), 7.13-7.07 (m, 2H), 6.38 (d, J=1.6Hz, 1H), 5.08 (s, 2H), 3.97 (s, 2H), 2.63 (s, 3H), 2.11 (s, 3H).
[0195] Example 12
[0196] Synthesis of {[5-(2-fluoropyridin-3-yl)-1-{3-[(2-methoxyethoxy)methyl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine (Compound 290)
[0197]
[0198] Step 1: Synthesis of 5-bromo-1-{3-[(2-methoxyethoxy)methyl]benzenesulfonyl}-1H-pyrrole-3-carbaldehyde (290-1)
[0199] Compound 280-1 (87 mg, 0.50 mmol) was dissolved in N, N-dimethylformamide (2.5 mL), cooled to 0°C, sodium hydride (26 mg, 0.65 mmol, 60% w / w) was added, stirred for 1 hour, and compound 249-5 (140 mg, 0.53 mmol) was added thereto. After reacting for 2 hours, saturated aqueous ammonium chloride solution (10 mL) was slowly added dropwise to the reaction solution, extracted with ethyl acetate (5 mL×2), the organic phase was washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, the solvent was concentrated, and column chromatography (V 正己烷 :V 乙酸乙酯=2:1) to obtain compound 290-1 (140 mg, yellow oil, yield: 69.6%).
[0200] Step 2: Synthesis of 5-(2-fluoropyridin-3-yl)-1-{3-[(2-methoxyethoxy)methyl]benzenesulfonyl}-1H-pyrrole-3-carbaldehyde (290-2)
[0201] Compound 290-1 (140 mg, 0.35 mmol), compound 280-6 (73 mg, 0.52 mmol), Pd(dppf)Cl2 (15 mg, 0.02 mmol), Na2CO3 (110 mg, 1.04 mmol) were dissolved in dioxane (6 mL) and water (0.6 mL), heated to 120 ° C under nitrogen protection and stirred for 4 hours, cooled to room temperature, ethyl acetate (20 mL) was added to dilute the reaction system, washed with water (10 mL) and saturated brine (10 mL) in turn, dried over anhydrous sodium sulfate, filtered, the solvent was concentrated and then column chromatography (V 正己烷 :V 乙酸乙酯 =2:1) to obtain compound 290-2 (30 mg, light yellow oil, yield 20.6%), [M+H] + :419.12.
[0202] Step 3: Synthesis of {[5-(2-fluoropyridin-3-yl)-1-{3-[(2-methoxyethoxy)methyl]benzenesulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine (290)
[0203] Compound 290-2 (30 mg, 0.07 mmol) was dissolved in methanol (2 mL), and methylamine methanol solution (1 mL, 30% w / w) was added at room temperature. After stirring for 2 hours, sodium borohydride (6 mg, 0.15 mmol) was added. The reaction solution was diluted with dichloromethane (10 mL), and the organic phase was washed with saturated ammonium chloride aqueous solution (4 mL) and saturated brine (4 mL) in sequence, dried over anhydrous sodium sulfate, filtered, and the solvent was concentrated. Column chromatography (V 二氯甲烷 :V 甲醇 =15:1) and then purified by reverse phase column preparation to obtain compound 290 (13 mg, yellow oil, yield: 41.8%), [M+H] + :434.16.
[0204] 1H NMR (400MHz, CD3OD) δ8.32-8.27 (m, 1H), 7.79 (d, J=1.9Hz, 1H), 7.74-7.63 (m, 2H), 7.54-7.47 (m, 1H), 7.47-7.41 (m, 2H), 7.44- 7.36 (m, 1H), 6.48 (d, J=1.9Hz, 1H), 4.53 (s, 2H), 4.09 (s, 2H), 3.69-3.62 (m, 2H), 3.62-3.56 (m, 2H), 3.38 (s, 3H), 2.70 (s, 3H).
[0205] Example 13
[0206] Synthesis of {[5-(2-fluorophenyl)-1-({5-[(2-methoxyethoxy)methyl]pyridin-3-yl}sulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (Compound 292)
[0207]
[0208] Step 1: Synthesis of 3-bromo-5-[(2-methoxyethoxy)methyl]pyridine (292-2)
[0209] Compound 292-1 (2.2 g, 10.7 mmol) was dissolved in N, N-dimethylformamide (15 mL), sodium hydride (704 mg, 17.6 mmol, 60% w / w) was added in batches at 0°C, and the reaction was continued for 20 minutes, followed by compound 249-2 (3.0 g, 21.4 mmol), and stirred at room temperature overnight. The reaction solution was poured into 80 mL of water, extracted with ethyl acetate (30 mL × 2), the organic phases were combined and washed with saturated brine (25 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (V 正己烷 :V 乙酸乙酯 =5:1) to obtain compound 292-2 (2.8 g, yellow oil, yield: 97.2%).
[0210] Step 2: Synthesis of 3-(benzylthio)-5-[(2-methoxyethoxy)methyl]pyridine (292-3)
[0211] Compound 292-2 (2.8 g, 11.4 mmol) was dissolved in toluene (30 mL), and then Pd2(dba)3 (394 mg, 0.43 mmol), Xantphos (249 mg, 0.43 mmol), DIEA (2.2 g, 17.1 mmol) and benzyl mercaptan (2.1 g, 17.1 mmol) were added in sequence, and stirred overnight at 100°C under nitrogen protection. After the reaction was completed, the reaction system was cooled to room temperature, and water (60 mL) was added to the reaction system to quench the reaction, and extracted with ethyl acetate (40 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =2:1) to obtain compound 292-3 (3.1 g, light yellow oil, yield: 94.2%).
[0212] Step 3: Synthesis of 5-[(2-methoxyethoxy)methyl]pyridine-3-sulfonyl chloride (292-4)
[0213] Compound 292-3 (518 mg, 1.79 mmol) was dissolved in acetonitrile (8 mL), cooled to 0°C, and then glacial acetic acid (0.8 mL), water (0.4 mL) and DCDMH (424 mg, 2.15 mmol) were added in sequence, and the mixture was kept warm for 2 hours. After the reaction was completed, ethyl acetate (30 mL) was added to the reaction system, and the mixture was washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =5:1) to obtain compound 292-4 (250 mg, colorless oil, yield: 52.6%).
[0214] Step 4: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-({5-[(2-methoxyethoxy)methyl]pyridin-3-yl}sulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (292-5)
[0215] Compound 249-6 (120 mg, 0.39 mmol) was dissolved in N, N-dimethylformamide (5 mL), cooled to 0°C, sodium hydride (19 mg, 0.47 mmol, 60% w / w) was added, stirred at room temperature for half an hour, and then compound 292-4 (125 mg, 0.47 mmol) was added, and stirred at room temperature overnight. The reaction was quenched with saturated ammonium chloride (25 mL), extracted with ethyl acetate (10 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯=1:1) to obtain compound 292-5 (96 mg, yellow oil, yield: 45.6%), [M+H] + :534.22.
[0216] Step 5: Synthesis of {[5-(2-fluorophenyl)-1-({5-[(2-methoxyethoxy)methyl]pyridin-3-yl}sulfonyl)-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (292)
[0217] Compound 292-5 (90 mg, 0.17 mmol) was dissolved in dichloromethane (5 mL), and a hydrochloric acid ethyl acetate solution (2 M, 2 mL) was added and stirred for 2 hours. The reaction solution was concentrated and slurried with ethyl acetate (3 mL) to give compound 292 (48 mg, gray solid, yield: 60.6%), [M+H] + :434.15.
[0218] 1 H NMR (400MHz, CD3OD) δ8.83 (s, 1H), 8.55 (s, 1H), 7.90-7.82 (m, 2H), 7.54 (tdd, J=7.4, 5.2, 1.8Hz, 1H), 7.24 (td, J=7.5, 1.1Hz, 1H), 7 .18-7.08 (m, 2H), 6.47 (d, J=1.9Hz, 1H), 4.62 (s, 2H), 4.13 (s, 2H), 3.75-3.65 (m, 2H), 3.65-3.55 (m, 2H), 3.40 (s, 3H), 2.73 (s, 3H).
[0219] Embodiment 14
[0220] Synthesis of {[5-(2-fluorophenyl)-1-{[5-(prop-2-en-1-oxy)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (Compound 294)
[0221]
[0222] Step 1: Synthesis of 3-(benzyloxy)-5-(benzylthio)pyridine (294-2)
[0223] Compound 294-1 (1.5 g, 5.68 mmol) was dissolved in toluene (20 mL), and then Pd2(dba)3 (522 mg, 0.57 mmol), Xantphos (645 mg, 1.13 mmol), DIEA (2.2 g, 17.04 mmol) and benzyl mercaptan (776 mg, 6.25 mmol) were added in sequence, and stirred overnight at 100°C under nitrogen protection. After the reaction was completed, the mixture was cooled to room temperature, and water (60 mL) was added to the reaction system to quench the reaction, and the mixture was extracted with dichloromethane (30 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =5:1) to obtain compound 294-2 (1.5 g, yellow oil, yield: 85.9%).
[0224] Step 2: Synthesis of 5-(Benzyloxy)pyridine-3-sulfonyl chloride (294-3)
[0225] Compound 294-2 (1.50 g, 4.88 mmol) was dissolved in acetonitrile (15 mL), cooled to 0°C, and then glacial acetic acid (1.5 mL), water (0.8 mL) and DCDMH (1.45 g, 7.36 mmol) were added in sequence, and the mixture was kept warm for half an hour. After the reaction was completed, ethyl acetate (40 mL) was added to the reaction system, and the mixture was washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =10:1) to obtain compound 294-3 (1.2 g, white solid, yield: 86.7%).
[0226] Step 3: Synthesis of tert-butyl N-[(1-{[5-(benzyloxy)pyridin-3-yl]sulfonyl}-5-(2-fluorophenyl)-1H-pyrrol-3-yl)methyl]-N-methylcarbamate (294-4)
[0227] Compound 249-6 (1.0 g, 3.29 mmol) was dissolved in N, N-dimethylformamide (10 mL), cooled to 0°C, sodium hydride (170 mg, 4.25 mmol, 60% w / w) was added, stirred at room temperature for half an hour, and then compound 294-3 (1.1 g, 3.89 mmol) was added, and stirred at room temperature for 3 hours. The reaction was quenched with saturated ammonium chloride (50 mL), extracted with ethyl acetate (20 mL×3), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =10:1) to obtain compound 294-4 (1.6 g, yellow oil, yield: 88.3%), [M+H]+ :552.20.
[0228] Step 4: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-[(5-hydroxypyridin-3-yl)sulfonyl]-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (294-5)
[0229] Compound 294-4 (1.5 g, 2.72 mmol) was dissolved in methanol (15 mL), palladium carbon (300 mg, containing 5% palladium and 55% water) was added, and the mixture was stirred at room temperature overnight under a hydrogen system. After the reaction was completed, the reaction solution was filtered and concentrated to obtain compound 294-5 (1.2 g, yellow oil, yield: 95.6%), [M+H] + :462.19.
[0230] Step 5: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-{[5-(prop-2-en-1-oxy)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (294-6)
[0231] Compound 294-5 (200 mg, 0.43 mmol) was dissolved in N, N-dimethylformamide (5 mL), and then cesium carbonate (280 mg, 0.86 mmol) and compound 253-2 (51 mg, 0.66 mmol) were added, and the mixture was sealed and reacted at 50°C for 2 hours. After the reaction was completed, the mixture was cooled to room temperature, and water (25 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Compound 294-6 (160 mg, yellow oil, yield: 73.6%) was obtained by reverse phase preparation and purification. [M+H] + :502.21. Step 6: Synthesis of {[5-(2-fluorophenyl)-1-{[5-(prop-2-en-1-oxy)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl]methyl}(methyl)amine hydrochloride (294)
[0232] Compound 294-6 (160 mg, 0.32 mmol) was dissolved in ethyl acetate (1 mL), and a hydrochloric acid ethyl acetate solution (2 M, 4 mL) was added and stirred for 2 hours. The reaction solution was concentrated and slurried with ether (3 mL) and ethyl acetate (1 mL) to obtain compound 294 (60 mg, lavender solid, yield: 43.0%), [M+H] + :402.12.
[0233] 1H NMR (400MHz, CD3OD) δ8.53 (d, J=2.8Hz, 1H), 8.20 (d, J=2.0Hz, 1H), 7.83 (s, 1H), 7.59-7.50 (m, 1H), 7.28-7.09 (m, 4H), 6.47 (d, J =2.0Hz, 1H), 6.12-5.98 (m, 1H), 5.42 (d, J = 17.2Hz, 1H), 5.35 (d, J = 10.4Hz, 1H), 4.62 (d, J = 5.2Hz, 2H), 4.13 (s, 2H), 2.74 (s, 3H).
[0234] Embodiment 15
[0235] Synthesis of (5-{[2-(2-fluorophenyl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}pyridin-3-yl)methanol (Compound 295)
[0236] Step 1: Synthesis of methyl (5-bromopyridin-3-yl)acetate (295-1)
[0237] Compound 292-1 (200 mg, 1.06 mmol) was dissolved in dichloromethane (5 mL), and then DMAP (13 mg, 0.11 mmol), triethylamine (215 mg, 2.12 mmol) and acetic anhydride (130 mg, 1.27 mmol) were added in sequence, and stirred at room temperature overnight. After the reaction was completed, water (20 mL) was added to the reaction system, and the mixture was extracted with dichloromethane (10 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =5:1) to obtain compound 295-1 (230 mg, brown oil, yield: 94.0%).
[0238] Step 2: Synthesis of methyl [5-(benzylthio)pyridin-3-yl]acetate (295-2)
[0239] Compound 295-1 (230 mg, 1.00 mmol) was dissolved in toluene (5 mL), and then Pd2(dba)3 (27 mg, 0.03 mmol), Xantphos (17 mg, 0.03 mmol), DIEA (258 mg, 2.00 mmol) and benzyl mercaptan (149 mg, 1.20 mmol) were added in sequence. The mixture was stirred at 100°C for 5 hours under nitrogen protection. After the reaction was completed, the mixture was cooled to room temperature, water (15 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V正己烷 :V 乙酸乙酯 =3:1) to obtain compound 295-2 (270 mg, brown oil, yield: 98.8%).
[0240] Step 3: Synthesis of methyl [5-(chlorosulfonyl)pyridin-3-yl]acetate (295-3)
[0241] Compound 295-2 (270 mg, 1.0 mmol) was dissolved in acetonitrile (5 mL), cooled to 0°C, and then glacial acetic acid (0.6 mL), water (0.3 mL) and DCDMH (236 mg, 1.2 mmol) were added in sequence, and the reaction was kept warm for 1 h. After the reaction was completed, ethyl acetate (25 mL) was added to the reaction system, and the mixture was washed with saturated brine (15 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =2:1) to obtain compound 295-3 (220 mg, yellow oil, yield: 89.0%).
[0242] Step 4: Synthesis of methyl (5-{[4-({[(tert-butoxy)carbonyl](methyl)amino}methyl)-2-(2-fluorophenyl)-1H-pyrrol-1-yl]sulfonyl}pyridin-3-yl)acetate (295-4)
[0243] Compound 249-6 (295 g, 0.97 mmol) was dissolved in N, N-dimethylformamide (5 mL), cooled to 0°C, sodium hydride (42 mg, 1.05 mmol, 60% w / w) was added, stirred at room temperature for half an hour, and then compound 295-3 (220 mg, 0.88 mmol) was added, and stirred at room temperature for 2 hours. The reaction was quenched with saturated ammonium chloride (25 mL), extracted with ethyl acetate (10 mL×3), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography (V 正己烷 :V 乙酸乙酯 =1:1) to obtain compound 295-4 (250 mg, yellow oil, yield: 49.8%), [M+H] + :518.17.
[0244] Step 5: Synthesis of tert-butyl N-{[5-(2-fluorophenyl)-1-{[5-(hydroxymethyl)pyridin-3-yl]sulfonyl}-1H-pyrrol-3-yl]methyl}-N-methylcarbamate (295-5)
[0245] Compound 295-4 (250 mg, 0.48 mmol) was dissolved in methanol (3 mL), lithium hydroxide (14 mg, 0.58 mmol) was dissolved in water (1.5 mL) and added to the reaction solution, and stirred for 3 hours. Water (5 mL) was added for dilution, and the mixture was extracted with ethyl acetate (10 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by reverse phase preparation to obtain compound 295-5 (225 mg, light yellow solid, yield: 98.0%), [M+H] + :476.17.
[0246] Step 6: Synthesis of (5-{[2-(2-fluorophenyl)-4-[(methylamino)methyl]-1H-pyrrol-1-yl]sulfonyl}pyridin-3-yl)methanol (295)
[0247] Compound 295-5 (225 mg, 0.47 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was poured into water (15 mL), and the pH was adjusted to 8 with sodium bicarbonate, and then extracted with dichloromethane (10 mL×3). The organic phase was dried over anhydrous sodium sulfate and filtered. After the filtrate was concentrated, the crude product was slurried with a mixed solvent of n-hexane (5 mL) and ethyl acetate (1 mL), and suction filtered to obtain compound 295 (35 mg, gray solid, yield 19.7%), [M+H] + :376.12.
[0248] 1 H NMR (400MHz, CDCl3) δ8.69 (d, J=1.9Hz, 1H), 8.45 (d, J=2.3Hz, 1H), 7.98 (t, J=2.2Hz, 1H), 7.63 (d, J=1.9Hz, 1H), 7.44 (dtt, J=8.2, 5.2, 3.2Hz, 1H), 7.18 (dd, J=5.8, 3.5Hz, 2H), 7.07 (t, J=9.0Hz, 1H), 6.36 (d, J=1.9Hz, 1H), 4.70 (s, 2H), 3.83 (s, 2H), 2.53 (s, 3H).
[0249] H + / K + -ATPase biological evaluation
[0250] The following in vitro screening assay was used to determine the effects of the compounds of the present invention on H + / K + -Inhibition of ATPase activity.
[0251] Experimental materials and instruments:
[0252] ATP, malachite green, valinomycin, ammonium molybdate
[0253] No K + Buffer: 50 mM Tris-HCl pH 6.5, 5 mM magnesium chloride, 10 μM valinomycin
[0254] Contains K + Buffer: 50 mM Tris-HCl pH 6.5, 5 mM magnesium chloride, 10 μM valinomycin, 20 mM KCl MLG colorimetric solution: 0.1% w / v malachite green, 1.5% w / v ammonium molybdate, 0.2% v / v Tween-20
[0255] Rabbit gastric mucosal microsomes (rich in H + / K + -ATPase), the extraction method is sucrose gradient centrifugation: the rabbit stomach is washed with tap water and 3MNaCl solution respectively, and then the surface water is removed with filter paper. Pre-cooled homogenization buffer (4mL / g tissue) is added and homogenized in a tissue homogenizer for 2-5 minutes. After homogenization, if there are larger tissue particles, they can be removed by centrifugation (600g, 10min), and then the supernatant is transferred to a clean centrifuge tube. After centrifugation at 20000g for 30min, the supernatant is transferred to a clean centrifuge tube and further centrifuged at 100000g for 90min to collect the precipitate; the precipitate is suspended with the homogenate and evenly dispersed, and the protein concentration is measured by Bradford method, and the concentration is adjusted to 10mg / mL; 7.5% Ficoll layering solution is added in equal proportions, and after centrifugation at 100000g for 60min, the middle layer (H + / K + -ATPaseenriched gastric membranes) in a clean centrifuge tube, dilute 4-5 times with homogenate, continue centrifugation at 100000g for 90 min, collect the precipitate; suspend the precipitate with homogenate, homogenize evenly, measure the protein concentration with Bradford method, adjust the concentration to 22.5 mg / mL, and freeze at -80℃ for later use.
[0256] Experimental process:
[0257] 45 μL buffer (containing K + 5 μL of gastric mucosal microsomes (H + / K +-ATPase), then add 5 μL of compound solution, then add 5 μL of 5 mM ATP to start the reaction, pre-react at 37°C for 30 min. Add 15 μL of malachite green solution to terminate the reaction, balance at room temperature for 20 min, and read the absorbance value at 620 nm.
[0258] At the same time, the reaction with the same volume but without KCl was performed as background and subtracted when calculating the enzyme activity.
[0259] Compound IC 50 The values were calculated by the inhibition rate at different concentrations. + / K + -ATPase has obvious inhibitory activity, IC 50 It is 20 to 100 nM, preferably 20 to 50 nM.
[0260]
[0261] Vonoprazan
[0262] IC of some compounds of the present invention 50 Value (H + / K + -ATPase) are shown in Table 1 below;
[0263] Table 1
[0264]
[0265] The compounds of the present invention have an effect on H + / K + -ATPase had obvious inhibitory activity and was significantly better than the control groups.
[0266] In vitro cytotoxicity assay
[0267] Using Dulbecco's modified Eagle's medium (DMEM; Invitrogen), the cell line HepG2 derived from human liver cancer was cultured and passaged at 5% and 37°C. The cells in the logarithmic growth phase were collected, counted, and resuspended with complete medium. The cell concentration was adjusted to the appropriate concentration (determined according to the results of the cell density optimization test), inoculated into a 96-well plate, and 75μL / well of the cell suspension was added according to the following platemap. The test compound was diluted to the corresponding action concentration set with the culture medium, and added to the cells according to the platemap 25μL / well. The action concentration of the test compound started from 100μM, with a 4-fold gradient dilution, a total of 9 concentrations, and 2 replicates. The cells were placed in an incubator at 37°C, 100% relative humidity, and 5% CO2 for 24h. 50μL / well CellTiter Glo RT was added and incubated in the dark for 30min. After gentle shaking, the detection was performed in Envision and the inhibition rate was calculated.
[0268] The inhibition rate of the drug on the growth of each cell was calculated according to the following formula: Cell growth inhibition rate % = (1-As / Ac)×100.
[0269] As: OA of sample (cells + CTG + test compound),
[0270] Ac: OA of normal growing cell control (cells+CTG+DMSO).
[0271] IC was calculated using the software Graphpad Prism 6 and the formula XY-analysis / Nonlinearregression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters). 50 Curve fitting and calculation of IC 50 The IC value of the compound of the present invention was found to be 50 Greater than 20μM, with low cytotoxicity.
[0272] Liver microparticle stability test
[0273] Prepare liver microsomes of the desired species (e.g., mouse, rat, dog, monkey, or human). Prepare 10 mM sample and positive control stock solutions using DMSO as the diluent. Then dilute all stock solutions to a working concentration of 0.25 mM with 70% acetonitrile. The cofactor used in this study is the NADPH regeneration system, which consists of 6.5 mM NADP, 16.5 mM G-6-P, and 3 U / mL G-6-PD. The quenching reagent is an acetonitrile solution containing tolbutamide and propranolol.
[0274] The buffer used in this study was 100 mM potassium phosphate buffer. A mixture containing 0.2 mg / mL liver microsomal protein and 1 μM test article / positive control was incubated in 100 mM potassium phosphate buffer.
[0275] 80 μL of each incubation solution was added to 300 μL of quenching reagent to precipitate protein and prepare a 0-minute sample. After vortexing the sample, 20 μL of NADPH regeneration system was added. 520 μL of each incubation solution was added to 130 μL of NADPH regeneration system to initiate the reaction. The final incubation conditions for 650 μL were: 0.2 mg / mL microsomal protein, 1 μM band / positive control, 1.3 mM NADP, 3.3 mM glucose 6-phosphate, 0.6 U / mL glucose 6-phosphate dehydrogenase. The mixture was placed in a 37°C water bath and gently shaken. 100 μL of the mixture was taken at 0, 5, 10, 30, and 60 minutes, respectively, placed on a 96-well plate containing 300 μL of quenching reagent to precipitate protein, and centrifuged (5000×g, 10 minutes). 80 μL of the supernatant was added to a 96-well detection plate pre-added with 160 μL of ultrapure water and analyzed by LC-MS / MS. Data processing to obtain the elimination half-life (T 1 / 2 , T 1 / 2 =0.693 / K) and in vitro clearance (Cl int ). The experiment found that the compound of the present invention has good liver microsome metabolic stability in SD rats.
[0276] Pharmacokinetic experiments
[0277] The compound under study is administered orally or intravenously (solvent 5% DMSO + 10% Solutol (HS-15) + 85% saline) to animals (such as mice, rats, dogs or monkeys) once, and blood is collected at fixed time points. Immediately after blood sampling, gently invert the test tube at least 5 times to ensure adequate mixing and then place on ice. The blood is anticoagulated with heparin and then centrifuged at 8000pm for 5 minutes to separate the serum from the red blood cells. The serum is aspirated with a pipette and transferred to a 2mL polypropylene tube, labeled with the name of the compound and the time point, and stored in a -40°C refrigerator before LC-MS analysis for testing. High-concentration samples are diluted with blank plasma for determination. After sample processing, the substances in the plasma are quantitatively analyzed by LCMS / MS. The plasma concentration / time curve obtained in this way is used to calculate pharmacokinetic parameters using a validated pharmacokinetic computer program. The experiment found that the compounds of the present invention have good pharmacokinetic properties.
[0278] In vivo efficacy studies
[0279] Study on the efficacy of drugs on the rat model of acute gastric ulcer induced by pylorus ligation
[0280] Thirty-two male SD rats (provided by Hunan Slake Jingda Experimental Animal Co., Ltd., weighing 200-220 g) were randomly divided into sham operation group (Sham), model group (Model), vonoprazan group (2.5 mg / kg), and compound 280 group (2.4 mg / kg) according to their body weight, with 8 rats in each group. Each group was orally administered with an equimolar dose of the salt compound by gavage, and the solvent was 5% DMSO + 10% Solutol (HS-15) + 85% saline.
[0281] Rats were fasted but not watered for 24 hours before modeling. Rats were weighed and given solvents or compounds according to groups and doses. One hour after administration, animals underwent gastric pyloric ligation. Rats were anesthetized with isoflurane using a respiratory anesthesia machine and fixed on the operating table in a supine position. Skin preparation, positioning and draping were performed around the incision. Under sterile conditions, povidone-iodine solution was used for disinfection and alcohol deiodination. The rat abdominal wall was cut open with an incision of about 2 cm. The abdominal cavity of the rat was opened with hemostats to expose the stomach. The junction of the stomach and duodenum was found, and then the pylorus was ligated (threaded at the junction of the stomach and duodenum). The abdominal wall incision was sutured and disinfected. All rats were fasted and watered after surgery. After fasting and watering for 16 hours after surgery, rats were euthanized, the whole stomach was removed, the stomach wall was cut open along the greater curvature of the stomach, gastric juice was collected in a centrifuge tube, centrifuged at 1500rpm for 15 minutes, the supernatant was aspirated, and the amount of gastric acid was recorded. The pH value of gastric juice in each group of rats was tested with a pH meter. After taking the gastric juice, the stomach was cut open, cleaned with saline, immersed in 1% formalin solution for 10 minutes, and the gastric mucosa was lined with white paper and flattened, and photographed and recorded. The ulcer size was measured with a vernier caliper, and the ulcer index was calculated. The evaluation criteria are shown in Table 2. The ulcer index (UI) and ulcer inhibition rate were calculated based on the score. The calculation formula is as follows:
[0282] UI=ΣA+Σ(B×C)
[0283] Ulcer inhibition rate = (ulcer index of model control group - ulcer index of drug administration group) / ulcer index of model group × 100%
[0284] Table 2 Gastric ulcer index scoring standard
[0285] Gastric mucosal damage 1 point 2 points 3 points 4 points 5 points Number of punctate bleeding (A) <5 5≤a<10 10≤ / / Ulcer area length (B) ≤1 1<b≤1.5 1.5<b≤2 2<b≤2.5 >2.5 Ulcer area width (C) ≤1 1<c≤2 2<c≤3 3<c≤4 >4
[0286] Note: The ulcer index is the sum of the scores of each lesion. a: number of bleeding points, b: length of the damaged area / mm, c: width of the damaged area / mm.
[0287] SPSS 22.0 was used for statistical analysis, and the mean ± standard error was used. The data of each group were analyzed and compared by one-way analysis of variance (ONE-WAY ANOVA), two-way analysis of variance (TWO-WAYANOVA) or T-TEST test. The statistical analysis results were considered to be significantly different when P < 0.05. The experimental results are shown in Table 3.
[0288] Table 3 Effects on gastric acidity and gastric ulcer in rats (n=8, )
[0289] Group Dosage (mg / kg) Gastric acidity (pH) Gastric ulcer index Gastric ulcer inhibition rate (%) Sham Group - 3.50±0.33 0 - Model Group - <![CDATA[1.84±0.35 ### ]]> <![CDATA[23.50±6.21 ### ]]> - Vonolazan 2.5 <![CDATA[4.80±1.56 *** ]]> <![CDATA[5.18±1.95 *** ]]> 77.96 Compound 280 2.4 <![CDATA[5.14±1.02 *** ]]> <![CDATA[4.63±1.77 *** ]]> 80.30
[0290] Note: Compared with the Sham group, p # <0.05, p ##<0.01, p ### <0.001; compared with the Model group, p * <0.05, p ** <0.01, p *** <0.001.
[0291] The experimental results show that compared with the model group, the compounds of the present invention have significantly increased gastric juice acidity (pH value) and significantly reduced ulcer index. The compounds of the present invention and vonoprazan both have significant anti-gastric ulcer effects. The gastric ulcer inhibition rate of the compounds of the present invention is higher than that of vonoprazan, and the anti-gastric ulcer effect is stronger than that of vonoprazan.
[0292] Study on the function of hERG potassium channel
[0293] Test system
[0294] Cells: Chinese hamster ovary (CHO) cell line, CHO-hERG cells were used in this experiment.
[0295] Cell culture medium and culture conditions: The complete culture medium is F12 medium supplemented with 10% fetal bovine serum and 1% Selective antibiotics (G418), 89 μg / mL hygromycin B (HB). The recovery medium is F12 medium supplemented with 10% fetal bovine serum. CHO-hERG cells are grown in a high humidity incubator at 37°C (±2°C) and 5% CO2 (4% to 8%). Cells are revived with recovery medium and passaged with complete medium. Cells used for patch clamp experiments are replaced with recovery medium at the last passage.
[0296] Extracellular and intracellular fluid components:
[0297] Reagents External solution (mM) Internal fluid (mM) <![CDATA[CaCl2]]> 2 5.37 <![CDATA[MgCl2]]> 1 1.75 KCl 4 120 NaCl 145 - Glucose 10 - HEPES 10 10 EGTA - 5 <![CDATA[Na2ATP]]> - 4 pH 7.3-7.4 7.2-7.3
[0298] Test methods
[0299] (1) Collect CHO-hERG cells in the exponential growth phase and resuspend them in ECS for later use.
[0300] (2) Manual patch clamp test
[0301] hERG currents were recorded under whole-cell patch clamp technique at room temperature. The output signal of the patch clamp amplifier was converted to digital and filtered at 2.9 kHz. Data were collected using Patchmaster Pro software.
[0302] The cells were placed in a cell recording tank on the stage of an inverted microscope, and a cell in the recording tank was randomly selected for testing. The perfusion system was fixed on the stage of an inverted microscope and the cells were continuously perfused with ECS.
[0303] Manual patch clamp recording microelectrodes were prepared using capillary glass tubes filled with intracellular fluid. On the day of the patch clamp experiment, electrodes were prepared using borosilicate glass tubes (BF150-117-10, SUTTER INSTRUMENT USA). The resistance of the electrodes after filling with ICS was between 2 and 5 MΩ.
[0304] The clamping voltage is -80mV, and the first step is to depolarize to +60mV and maintain for 850ms to open the hERG channels. Then, the voltage is set to -50mV and maintained for 1275ms to generate a rebound current or tail current, the peak of which will be measured and used for analysis. Finally, the voltage is returned to the clamping voltage (-80mV). During the experiment, this command voltage program is repeated every 15s.
[0305] At the beginning of recording of the perfusion of the solvent control working solution, monitor the tail current peak until more than 3 scanning curves are stabilized, then the test sample / positive control working solution to be tested can be perfused until the inhibitory effect of the test sample / positive control working solution on the hERG current peak reaches a stable state. Generally, the basic coincidence of the peak values of the three most recent consecutive current curves is used as the criterion for judging whether it is in a stable state. After reaching a stable state, continue to perfuse the next concentration of the test sample. One or more test samples / positive controls, or multiple concentrations of the same drug, can be tested on one cell. Different test samples / positive controls need to be rinsed with solvent control working solution until the hERG current returns to more than 80% of the size before the addition of the drug. The standard deviation of the inhibition rate of each recorded cell at the same concentration shall not exceed 15%.
[0306] The positive control cisapride was tested at a concentration of 0.1 μM, and the cells were assayed in duplicate. According to scientific literature reports, 0.1 μM cisapride inhibits hERG current by more than 50%. (Milnes, JT, et al.).
[0307] (3) Manual patch clamp data acceptance criteria
[0308] Sealing standard: After the whole-cell mode is formed, the clamping voltage (-80mV) is applied, and the cell membrane related parameters (Cm, Rm and Ra) can be recorded. A good whole-cell recording should meet the following conditions: path resistance (Rs) is less than 10MΩ; membrane resistance (Rm) is greater than 500MΩ and membrane capacitance (Cm) is less than 100pF.
[0309] Current size: The peak current amplitude before the test article / positive control is between 400pA and 5000pA. Otherwise, the cell is discarded.
[0310] Leakage current: At a clamp voltage of -80mV, the absolute value of the leakage current should be less than 200pA. The current amplitude will be corrected using the leakage current at -80mV. Scans with leakage currents greater than 200pA cannot be used for analysis.
[0311] Data analysis
[0312] For each cell, the inhibition percentage of each concentration of the test article and positive control was calculated from the recorded current response using the following formula: (1-peak tail current recorded after perfusion of the test article / positive control / peak tail current (starting current) recorded after perfusion of the vehicle control) × 100%.
[0313] For each concentration, all cell inhibition percentages were recorded and averaged, IC 50 The values were obtained from the concentration-effect curves by the Hill fitting method.
[0314] The experiment found that the compound of the present invention has a higher hERG IC 50 This indicates that the compound of the present invention has a low risk of cardiotoxicity.
[0315] Acute toxicity test
[0316] The compound was intravenously administered once (solvent 5% DMSO + 10% Solutol (HS-15) + 85% saline) to SD rats (10 animals / group, half male and half female), and each group was administered with an equimolar dose of the salt compound. The specific dosage is shown in Table 2. Clinical observation was performed after administration. Clinical observation was performed twice on the first day, once a day from the second day, for 14 consecutive days. It included behavioral observation, whole body touch examination, cavity observation: including skin, mucous membranes, hair color, eyes, respiration, autonomic activity and nervous system behavior and death, and recorded poisoning signs and death. The experimental results are shown in Table 4.
[0317] Table 4: Results of the preliminary acute toxicity test of the tested compounds in rats
[0318]
[0319] The compound of the present invention has good safety. The death percentage of rats after single intravenous administration of the compound provided by the present invention at an equimolar dose is significantly lower than that of the control group (vonoprazan fumarate), indicating that the compound of the present invention has good safety.
[0320] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0321] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A pyrrolesulfonyl derivative, its tautomer or stereoisomer, and a pharmaceutically acceptable salt thereof, It is characterized in that The structure of the pyrrole sulfonyl derivative is shown in formula (I): Wherein, T is selected from O or C 1-6 alkyl; When T is selected from O, X is selected from not present, R2 is selected from C 2-6 alkenyl; When T is selected from C 1-6 When alkyl, X is selected from O, S, NH, S(O) m , R2 is selected from H, C 1-6 Alkyl, -C(=O)-C 1-6 Alkyl, C 2-6 Alkenyl, the C 1-6 The alkyl group may be optionally further substituted with methoxy, halogen; R1 is selected from halogen; R3 is selected from H, halogen, CH3O-; Z1 and Z2 are each independently selected from C and N; m is selected from 1 and 2; n is selected from 0, 1, 2, 3, 4, 5.
2. The pyrrole sulfonyl derivative, its tautomer or stereoisomer, and a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The structure of the pyrrole sulfonyl derivative is shown in formula (II): Wherein, X is selected from O, S, NH, S(O) m ; R1, R2, n, m, Z1, and Z2 are as defined in claim 1.
3. The pyrrole sulfonyl derivative, its tautomer or stereoisomer, and pharmaceutically acceptable salt thereof according to claim 1, characterized in that: Said: R1 is selected from fluorine; n is selected from 0, 1, 2.
4. A pyrrolesulfonyl derivative, its tautomer or stereoisomer, and a pharmaceutically acceptable salt thereof, It is characterized in that The structure of the pyrrole sulfonyl derivative is shown in formula (III): Among them, R a Selected from H, halogen, C 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 Alkyl; among which C 1-6 The alkyl group may be optionally further substituted with 1, 2, or 3 fluorine atoms; R1, R3, n, Z1, and Z2 are as defined in claim 1.
5. The pyrrole sulfonyl derivative, its tautomer or stereoisomer, and pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The pyrrole sulfonyl derivative is selected from any one of the following structures:
6. The pyrrole sulfonyl derivative, its tautomer or stereoisomer, and a pharmaceutically acceptable salt thereof according to claim 4, characterized in that: The pyrrole sulfonyl derivative is selected from any one of the following structures:
7. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the pyrrole sulfonyl derivative according to any one of claims 1 to 6, its tautomer or stereoisomer, and a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and / or excipient.
8. The pyrrole sulfonyl derivatives, tautomers or stereoisomers thereof, and pharmaceutically acceptable salts thereof according to any one of claims 1 to 6, or the pharmaceutical composition according to claim 7, in the preparation of a gastric acid secretion inhibitor, H + / K + - Use in ATPase inhibitors or potassium ion competitive acid blockers.
9. Use of the pyrrole sulfonyl derivative, its tautomer or stereoisomer, and its pharmaceutically acceptable salt as described in any one of claims 1 to 6, or the pharmaceutical composition as described in claim 7 in the preparation of drugs for treating or preventing the following diseases: peptic ulcer, Zollinger-Ellison syndrome, erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease, Barrett's esophagitis, functional dyspepsia, Helicobacter pylori infection, gastric cancer, gastric MALT lymphoma, ulcer caused by non-steroidal anti-inflammatory drugs, hyperacidity caused by postoperative stress, or ulcer caused by postoperative stress; or use in the preparation of drugs for inhibiting upper gastrointestinal bleeding caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis or invasive stress.
Citation Information
Cited By
4-(methylthio)pyrrole derivative
WO2026135359A1
